mRNA medicine · Protein replacement: CFTR gene mutation · developed by Arcturus Therapeutics
ARCT-032 is a CFTR mRNA formulated in lipid nanoparticles. It delivers messenger RNA encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, intended to supply the protein in people with cystic fibrosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06747858 | Phase 2 | Cystic Fibrosis | Recruiting | ARCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CFTR Gene MutationCystic Fibrosis
Updated Oct 11, 2026. Something wrong or missing? Report it on the ARCT page.
See ARCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ARCT catalysts and pipeline →